BI 1291583 5 mg clinical trials

A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)

This study looks into a new tablet called BI 1291583 for adults with cystic fibrosis bronchiectasis. We want to see if it's safe, how well people tolerate it, and how it works in the body compared to a dummy pill.